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In high-burden countries, Mycobacterium bovis Bacillus Calmette-Gu´ erin (BCG) vaccine is administered in newborn to prevent
severe Mycobacterium tuberculosis infection. Because life-threatening disseminated BCG disease may occur in children with
primary immunodeﬁciency, vaccination strategy against tuberculosis should be redeﬁned in non-high-burden countries. We
report the case of a patient with X-linked severe combined immunodeﬁciency (SCID) who developed disseminated BCG disease,
highlighting the speciﬁc strategies adopted.
1.Introduction
Bacillus Calmette-Gu´ erin (BCG) vaccine is administered
worldwide to prevent severe Mycobacterium tuberculosis
infection. BCG vaccine has an excellent safety proﬁle [1], but
a wide range of complications can occur (from simple local
lymphadenitis to almost universally lethal disseminated dis-
ease)[2].Itisnowacceptedthatmostpatientswithmoderate
to severe complications have underlying immunodeﬁciency
[3]. Several genetic defects that correlate with BCG disease
have now been identiﬁed, such as Mendelian susceptibility
to Mycobacterial disease (IFN-γ-IL-12 pathway), hyper-IgM
syndrome, chronic granulomatous disease, and SCID [4].
BCG is part of the Portuguese Immunization Program
since 1965, being administered at birth to children with
weight above 2000 grams.
We report a patient with SCID with disseminated BCG
disease and highlight speciﬁc strategies adopted in patient’s
treatment.
2. Case Presentation
A 5-months-old boy was admitted to the intensive care unit
of a tertiary pediatric hospital in Lisbon for respiratory
insuﬃciency following three days of fever, cough, and wors-
ening respiratory distress. He presented with oral thrush,
bilateral pulmonary rales, and hepatosplenomegaly. He had
been vaccinated at birth with BCG (Danish strain 1331) and
had had recurrent infections (conjunctivitis, otitis media,
and persistent oral thrush).
Therewasnoconsanguinity.Twomaternalunclesdiedof
pneumonia in infancy.
ThechestX-rayrevealedabsenceofathymusandshowed
bilateral areas of opacities (Figure 1). The immunologic
panel conﬁrmed the hypothesis of SCID (Table 1), later
genetically characterized (missense mutation in exon 5,
codon 226 CGC→CAC, leading to an arginine 226 substitu-
tion by histidine; common cytokine receptor gamma chain
of IL-2—IL2RG gene). This mutation has previously been
described as causing human X-linked SCID [5].2 Case Reports in Medicine
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Figure 1: Chest X-ray.
Although being asymptomatic, chimerism studies were
performed to assess the presence of exogenous maternal
lymphocytes, which can be important for an early diagnosis
and for the choice of the conditioning regimen if bone
marrow transplantation is considered. The results conﬁrmed
that 75% of total lymphocyte count was maternal.
The bronchoalveolar lavage was positive for Candida
albicans, Pneumocystis jiroveci, and acid-fast bacilli. An ultra-
sound evaluation showed an enlarged spleen with nodules.
The BCG primer-speciﬁc polymerase chain reaction quickly
identiﬁed the infection by BCG (ampliﬁcation of pncA gene1
and a multiplex PCR that targets the RD1 region for BCG
[6–8]), and presumptive diagnosis of disseminated BCG was
made.
He was treated with trimethoprim-sulfamethoxazole and
a four-tuberculostatic drug regimen, comprised of isoni-
azid, rifampin, ethambutol, and levoﬂoxacin, according to
laboratory data regarding BCG strain susceptibility. The
infant started antibacterial and antifungal prophylaxis and
immunoglobulin replacement therapy.
Splenectomy was performed aiming for a reduction in
BCG load which could worsen the prognosis following
immune reconstitution. Spleen analysis revealed severe BCG
inﬁltration (Figure 2), thus establishing the deﬁnitive diag-
nosis of disseminated BCG disease. Four and a half months
afterthestartof tuberculostatictherapy, T-celldepleted bone
marrow transplantation (BMT) from an unrelated 10/10
HLA matched donor following reduced intensity condition-
ing with treosulfan, ﬂudarabine and campath was performed
(graft contained 12,5 × 106/kilograms CD34+ stem cells).
Toenhanceimmunereconstitution,donorlymphocyteswere
administered at d + 31, d + 61, and d + 88 containing 5,
15, and 50 × 104 CD3+ T cells per kilograms, respectively.
The transplant course was uneventful with the exception
of repeated periods of fever that, in the absence of other
reported infections, were probably related to active BCG
infection, treated continuously by isoniazid, rifampin, and
ethambutol. Haematological reconstitution occurred within
normal time frame, and there were no signs of graft-versus-
host disease. About three months after transplantation,
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Figure 2: Histologic appearance of spleen sections stained with
hematoxylinandeosin(a)andwithZiehl-Neelsen(b)showingBCG
inﬁltration (arrows).
relevant numbers of T cells become detectable. During
this phase of immunological reconstitution, signs of BCG
infection augmented with prominent nodules at the BCG
inoculation site (Figure 3), enlarged thoracic and abdominal
lymph nodes, fever, leukocytosis, and massive elevation of
C-reactive protein. Linezolid was added to other antitu-
berculous drugs, and some short courses of steroids were
administered. The child remained in good clinical condition
and is alive and well to date.
3. Discussion
We report a case of X-linked SCID with disseminated BCG
disease. SCID is the most severe form of primary immun-
odeﬁciency disease, characterized by defective T-lymphocyte
diﬀerentiation that leads to early death in the absence of
hematopoietic stem cell transplantation. Patients usually
present severe and life-threatening opportunistic infections
early in infancy such as disseminated BCG infection [9].
Prevalence data of primary immunodeﬁciency disease
(PID) are not available in Portugal. In the USA, the
prevalence rate of PID is estimated to be 1:2000 children
[10] and there are more than 200 cases of disseminated
BCG infection in this group of patients [11]. Its estimated
incidence is 0.1 to 4.3 per one million vaccinated children
and is lethal in 50 to 71% of cases [2, 3, 12]. The availability
of the new polymerase chain reaction primers that allow the
distinctionbetween Mycobacteriumtuberculosisandbovisisa
useful tool in the management of these patients, allowing for
quicker diagnosis thus preventing the use of nonappropriate
drugs.
Patients with SCID previously vaccinated with BCG are
diﬃcult to manage and should be kept under prophylactic
three drug regimens (without pyrazinamide, for which BCG
is primarily resistant [13]) after exclusion of disseminated
disease and until complete immunologic reconstitution
occurs after BMT.Case Reports in Medicine 3
Table 1: Laboratory results. ∗Maternal T cells in chimerism analysis. #Total chimerism 60% donor, 40% patient. Myeloid chimerism 100%
patient, T and NK cell chimerism 100% donor.
Laboratory test Patient prior to
transplantation
Patient 3 months after
transplantation
Patient 6 months after
transplantation Reference value
Serum immunoglobulins
IgA (mg/mL) <0.1 0.12 0.15 0.2–0.6
IgG (mg/mL) 0,63 Substituted Substituted 2.3–4.4
IgM (mg/mL) 0,351 0.79 0.32 0.3–0.9
Vaccine titers
Diphtheria (IU/mL) 0.25 Not done Not done >0.5
Tetanus (IU/mL) 0.13 Not done Not done >0.5
Isohemagglutinins Undetected Not done Not done >1/16
Lymphocyte subsets
CD3+ (cells/μL) 345∗ 124 1098 2300–6500
CD3+CD4+ (cells/μL) 8 69 960 1500–5000
CD3+CD4+CD45RA (%) <1 62% 84% 64–92
CD3+CD8+ (cells/μL) 339∗ 13 91 500–1600
CD3+CD8+CD45RA (%) 0 53–88
CD19+ (cells/μL) 210 1062 3477 600–1300
CD56+ (cells/μL) 18 165 127 100–1000
Lymphocyte proliferation
Phytohemagglutinin (SI) 3 86
Anti-CD3 (SI) 1 24
PPD (SI) 1 9
Vβ TCR repertoire restricted Not done Not done
Chimerism 75% maternal 100% donor 60% donor#
Viral loads and PCR
CMV, EBV, HSV,
All negative All negative All negative HIV1/2,HBV,HCV,
HHV6/7,VZV,
Enterovirus, Adenovirus
PCR Norovirus Not done + +
(a) (b)
Figure 3: BCG vaccination site at the time of immune reconstitution (a) 5 months after transplantation and (b) 5.5 months after
transplantation, showing skin ulceration with massive inﬁltration of BCG.4 Case Reports in Medicine
There are no clear guidelines on the most suitable
treatment for disseminated BCG disease [14, 15]. In this
case, aggressive therapy (comprising four drugs: isoniazid,
rifampicin, ethambutol, and levoﬂoxacin) was administered
for four and a half months prior to BMT to reduce the
BCG load. For the same reason, splenectomy was performed
prior to BMT.Since BCGitis is known to exacerbate clinically
during immune reconstitution leading to sepsis and fatal
multiple organ failure when T cells rapidly rise after BMT
[16], the following modiﬁcations of transplant procedure
were performed in this case: (a) reduced intensity condi-
tioning using treosulfan and ﬂudarabine instead of the stan-
dard regimen (busulfan and cyclophosphamide) to reduce
toxicity; (b) T cell depletion of the HLA-identical graft to
circumvent BCGitis exacerbation due to rapidly expanding
peripheral T cells in the graft; (c) donor lymphocytes in
escalating doses to induce a slow but stable T-cell reconsti-
tution; (d) immunosuppression with prednisolone to treat
cytokine reactions at the time of overwhelming immune
reconstitution. Of course, tuberculostatic drugs have to be
administered during the BMT procedure until clinical signs
of BCG disappear, which may take several months. In case
of empirical treatment, it should be taken into account that
BCG vaccine strains diﬀer in their susceptibility pattern to
antituberculous drugs and this should be sought.
In countries where the diagnosis of cellular PID (espe-
cially SCID) is well below expected, the possibility of a fatal
outcome due to the administration of BCG vaccine in the
neonatal period (before the suspicion of cellular PID) is a
reality.
The incidence of tuberculosis in Portugal has been dras-
tically decreasing (from 60:100.000 in 1990 to 24:100.000
in 2009, of which 5:100.000 in children under ﬁve years
old), and the extrapulmonary forms comprise about 30%
of all cases (notably, in 2009 only two cases of “severe”
extrapulmonary tuberculosis were reported in children)
[17]. This is due to improved public health and social
measures, but probably also to the protective eﬀect of BCG
vaccination, which is diﬃcult to assess.
Based on this trend and being aware that the diagnosis of
cellular PID remains below expected, the authors underline
the need to redeﬁne the vaccination strategy against tuber-
culosis in Portugal, namely, postponing its administration to
the second semester of life in regions where the incidence of
the disease is still above 20:100.000.
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